Carregant...
Phase I Trial of Dasatinib, Lenalidomide, and Temozolomide in Children with Relapsed or Refractory Central Nervous System Tumors
BACKGROUND: Single agent studies targeting the tumor microenvironment in central nervous system (CNS) tumors have largely been disappointing. Combination therapies targeting various pathways and cell types may be a more effective strategy. In this phase I study, we evaluated the combination of dasat...
Guardat en:
| Publicat a: | J Neurooncol |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5930136/ https://ncbi.nlm.nih.gov/pubmed/29427149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-018-2791-y |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|